Cell and Gene Therapies
Capability
TIA brings together five leading cell and gene therapy development
and manufacturing facilities in Australia to facilitate the translation
from discovery to clinical benefit, ensuring that manufacturing occurs
in compliance with regulations and that products entering clinical
trials are of a sufficiently high standard.
TIA has partnered with CCRM Australia, an organisation that accelerates the commercialisation of Australian regenerative medicine therapies and related technologies. CCRM achieves this through engagement and fostering local and international collaboration between industry, clinicians and academia.
